Zymeworks is a global biotechnology company developing and managing a portfolio of differentiated biotherapeutics to improve the standard of care for patients with difficult-to-treat cancers and autoimmune diseases. Leveraging our proprietary antibody engineering platforms, we are advancing a diverse pipeline of multispecific antibodies and antibody-drug conjugates, alongside partnered programs including Ziihera® (zanidatamab-hrii). Our integrated R&D engine and strategic partnerships enable the novel design of next-generation antibody therapeutics addressing significant unmet medical need.
Everlywell is a digital health company pioneering the next generation of biomarker intelligence—combining AI-powered technology with human insight to deliver personalized, actionable health answers. We transform complex biomarker data into life-changing insights, seamlessly integrating advanced diagnostics, virtual care, and patient engagement to reshape how and where health happens.
Over the past decade, Everlywell has delivered close to 1 billion personalized health insights, transforming care for 60 million people and powering hundreds of enterprise partners including 8 of the top 10 largest health plans in the U.S. From chronic condition management to preventive screening, our customizable remote-based solution helps close critical care gaps and deliver measurable health outcomes at scale. Backed by a nationwide clinical network, integrated lab, and AI-powered platform, Everlywell enables seamless, at-home care that meets today's needs and leads the way into tomorrow's healthcare.
Seed Health is a microbiome science company pioneering applications of microbes for human and planetary health. In collaboration with leading academic researchers, we advance breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics, consumer health innovations and environmental solutions. All consumer innovations in probiotics are commercialized under Seed®.